Espero Pharmaceuticals Inc., of Jacksonville, Fla., said it inked an exclusive licensing and distribution agreement with G. Pohl-Boskamp GmbH & Co., of Hohenlockstedt, Germany, for Pohl-Boskamp's nitroglycerin sublingual powder formulation to treat an attack or for prophylaxis of angina pectoris for the U.S. market.